{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:28:33Z","timestamp":1793381313451,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":191,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Psoriasis is a systemic inflammatory disease often accompanied by comorbidities, including metabolic syndrome, cardiovascular diseases and depression. Up to 41% of psoriasis patients develop psoriatic arthritis (PsA), making it one of the most relevant manifestations. A large health claims data set was analysed to determine the rate of PsA development in psoriasis patients. Furthermore, comorbid disease profiles of psoriasis patients with or without PsA were compared, and potential risk factors for the development of PsA were identified.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a non-interventional, retrospective analysis of anonymized insurance health claims data using a subset of the Institute of Applied Health Research Berlin (InGef) database. The primary outcome was the prevalence and incidence of diagnosed PsA among psoriasis patients in Germany. Risk factors for the development of PsA in psoriasis patients were determined by conditional logistic regression analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The cumulative percentage of patients with existing psoriasis developing concomitant PsA over 4 years was 3.44%, with a mean time to diagnosis of PsA of 1.5 years. Psoriasis patients diagnosed with acute rheumatism (odds ratio: 2.93, 95% CI\u2009=\u20091.76, 4.86; P\u2009&amp;lt;\u20090.001) or pain in unspecific joints (odds ratio: 1.74, 95% CI\u2009=\u20091.01, 2.99; P\u2009=\u20090.047) showed an increased risk for development of PsA later on. Interestingly, fewer than half of the patients with concomitant PsA consulted a rheumatologist.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Unspecific arthritic symptoms are likely to precede PsA diagnoses and can develop soon after onset of psoriasis, with accumulating risk over time. There is a high unmet need for early rheumatological assessment of psoriasis patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkaa033","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T16:34:30Z","timestamp":1594398870000},"source":"Crossref","is-referenced-by-count":19,"title":["Psoriatic arthritis epidemiology, comorbid\u00a0disease profiles and risk factors: results from a claims database analysis"],"prefix":"10.1093","volume":"4","author":[{"given":"J\u00fcrgen","family":"Rech","sequence":"first","affiliation":[{"name":"Department of Internal Medicine 3 - Rheumatology and Immunology, Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sticherling","sequence":"additional","affiliation":[{"name":"Hautklinik, Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Stoessel","sequence":"additional","affiliation":[{"name":"Elsevier Health Analytics, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona H C","family":"Biermann","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH, N\u00fcrnberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M","family":"H\u00e4berle","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH, N\u00fcrnberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Reinhardt","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH, N\u00fcrnberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"2020102411110558100_rkaa033-B1","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2020102411110558100_rkaa033-B2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1055\/s-0030-1252022","article-title":"Epidemiology of psoriasis in Germany\u2014analysis of secondary health insurance data","volume":"73","author":"Sch\u00e4fer","year":"2011","journal-title":"Gesundheitswesen"},{"key":"2020102411110558100_rkaa033-B3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.det.2014.09.004","article-title":"Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities","volume":"33","author":"Ryan","year":"2015","journal-title":"Dermatol Clin"},{"key":"2020102411110558100_rkaa033-B4","first-page":"891","article-title":"The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study","volume":"146","author":"Kurd","year":"2010","journal-title":"Arch Dermatol"},{"key":"2020102411110558100_rkaa033-B5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40259-013-0025-6","article-title":"Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents","volume":"27","author":"Gan","year":"2013","journal-title":"BioDrugs"},{"key":"2020102411110558100_rkaa033-B6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/rheumatology\/ker365","article-title":"Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone","volume":"51","author":"Rosen","year":"2012","journal-title":"Rheumatology (Oxford"},{"key":"2020102411110558100_rkaa033-B7","first-page":"809","article-title":"Longitudinal study of clinical and radiological progression in psoriatic arthritis","volume":"17","author":"Gladman","year":"1990","journal-title":"J Rheumatol"},{"key":"2020102411110558100_rkaa033-B8","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/rheumatology\/keg217","article-title":"Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study","volume":"42","author":"McHugh","year":"2003","journal-title":"Rheumatology (Oxford"},{"key":"2020102411110558100_rkaa033-B9","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1365-2133.2008.09023.x","article-title":"Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis","volume":"160","author":"Reich","year":"2009","journal-title":"Br J Dermatol"},{"key":"2020102411110558100_rkaa033-B10","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaad.2015.05.001","article-title":"Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis","volume":"73","author":"Villani","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2020102411110558100_rkaa033-B11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2020102411110558100_rkaa033-B12","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrrheum.2011.125","article-title":"Management of psoriatic arthritis from the view of the dermatologist","volume":"7","author":"Chang","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2020102411110558100_rkaa033-B13","first-page":"ii14","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2020102411110558100_rkaa033-B14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/09546630600823369","article-title":"Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists\u2019 offices","volume":"17","author":"Gottlieb","year":"2006","journal-title":"J Dermatolog Treat"},{"key":"2020102411110558100_rkaa033-B15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.sder.2005.01.006","article-title":"Psoriatic arthritis and psoriasis: need for a multidisciplinary approach","volume":"24","author":"Qureshi","year":"2005","journal-title":"Semin Cutan Med Surg"},{"key":"2020102411110558100_rkaa033-B16","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1136\/annrheumdis-2015-208821","article-title":"Subclinical joint inflammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysis","volume":"75","author":"Faustini","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020102411110558100_rkaa033-B17","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"2020102411110558100_rkaa033-B18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","article-title":"Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis","volume":"74","author":"Mease","year":"2014","journal-title":"Drugs"},{"key":"2020102411110558100_rkaa033-B19","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1136\/ard.2011.150938","article-title":"Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?","volume":"70","author":"Gladman","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2020102411110558100_rkaa033-B20","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2012-201706","article-title":"High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires","volume":"72","author":"Haroon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2020102411110558100_rkaa033-B21","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European s3-guidelines on the systemic treatment of psoriasis vulgaris \u2013 Update 2015 \u2013 Short version \u2013 EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2020102411110558100_rkaa033-B22","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1111\/jdv.14454","article-title":"European S3-Guideline on the systemic treatment of psoriasis vulgaris \u2013 Update Apremilast and Secukinumab \u2013 EDF in cooperation with EADV and IPC","volume":"31","author":"Nast","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2020102411110558100_rkaa033-B23","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/bjd.12230","article-title":"Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort","volume":"168","author":"Danielsen","year":"2013","journal-title":"Br J Dermatol"},{"key":"2020102411110558100_rkaa033-B24","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/acr.20401","article-title":"Incidence of arthritis in a prospective cohort of psoriasis patients","volume":"63","author":"Eder","year":"2011","journal-title":"Arthritis Care Res (Hoboken"},{"key":"2020102411110558100_rkaa033-B25","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/acr.23743","article-title":"Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: a population-based study","volume":"71","author":"Eder","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2020102411110558100_rkaa033-B26","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bjd.15021","article-title":"Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study","volume":"176","author":"Springate","year":"2017","journal-title":"Br J Dermatol"},{"key":"2020102411110558100_rkaa033-B27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/247553031016a00403","article-title":"Which psoriasis patients develop psoriatic arthritis?","volume":"16","author":"Busse","year":"2010","journal-title":"Psoriasis Forum"},{"key":"2020102411110558100_rkaa033-B28","doi-asserted-by":"crossref","first-page":"e0004","DOI":"10.5041\/RMMJ.10279","article-title":"Comorbidities in patients with psoriatic arthritis","volume":"8","author":"Haddad","year":"2017","journal-title":"Rambam Maimonides Med J"},{"key":"2020102411110558100_rkaa033-B29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/pds.3895","article-title":"Characteristics and external validity of the German Health Risk Institute (HRI) Database","volume":"25","author":"Andersohn","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2020102411110558100_rkaa033-B30","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00296-018-4124-z","article-title":"Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis","volume":"38","author":"Kr\u00fcger","year":"2018","journal-title":"Rheumatol Int"},{"key":"2020102411110558100_rkaa033-B31","author":"Ho","year":"2004"},{"key":"2020102411110558100_rkaa033-B32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00393-009-0462-2","article-title":"Detection of psoriasis arthritis with the GEPARD patient questionnaire in a dermatologic outpatient setting","volume":"69","author":"H\u00e4rle","year":"2010","journal-title":"Z Rheumatol"},{"key":"2020102411110558100_rkaa033-B33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13075-018-1653-5","article-title":"Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study","volume":"20","author":"Kampylafka","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2020102411110558100_rkaa033-B34","first-page":"199","article-title":"OP0305 Disease interception in psoriasis patients with subclinical joint inflammation by interleukin 17 inhibition with secukinumab \u2013 data from a prospective open label study","volume":"77(Suppl 2","author":"Kampylafka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020102411110558100_rkaa033-B35","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1468-3083.2009.03463.x","article-title":"The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics","volume":"24","author":"Christophers","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2020102411110558100_rkaa033-B36","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00403-012-1281-x","article-title":"Not simply a matter of psoriatic arthritis: epidemiology of rheumatic diseases in psoriatic patients","volume":"304","author":"De Marco","year":"2012","journal-title":"Arch Dermatol Res"},{"key":"2020102411110558100_rkaa033-B37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2005.03.046","article-title":"Epidemiology of psoriatic arthritis in the population of the United States","volume":"53","author":"Gelfand","year":"2005","journal-title":"J Am Acad Dermatol"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkaa033\/33482145\/rkaa033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumap\/article-pdf\/4\/2\/rkaa033\/34012701\/rkaa033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumap\/article-pdf\/4\/2\/rkaa033\/34012701\/rkaa033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T15:12:33Z","timestamp":1603552353000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkaa033\/5869812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkaa033","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020]]},"published":{"date-parts":[[2020]]},"article-number":"rkaa033"}}